Ultrahigh-content imaging helps to identify CAR target candidates against pancreatic adenocarcinoma
Sponsor
Join Dr. Daniel Schäfer, Team Coordinator R&D at Miltenyi Biotec, as he talks us through a recent and exciting development in the fight to make cancer history.
Making use of the innovative MICS (MACSima™ Imaging Cyclic Staining) technology, Dr. Schäfer has managed to bypass a major roadblock prohibiting effective cellular immunotherapy of pancreatic ductal adenocarcinoma: a lack of suitable tumor-specific antigens.
This research has allowed the positive identification of four target candidates from among 371 antigens, and the subsequent generation of 32 CARs to evaluate for therapeutic approaches. Dr. Schäfer will explain not just how this was accomplished, but also how CAR T cell activity was evaluated in vitro, and promising constructs in vivo, with efficacies ranging from stabilized disease to complete tumor eradication!
Dr. Schäfer’s approach offers a tantalizing glimpse at the new possibilities opened by the introduction of the MACSima Imaging Platform.
- How MICS technology with the MACSima Imaging Platform enables ultrahigh-content imaging
- How ultrahigh-content imaging helps to identify CAR targets
- How this technology can be combined with flow cytometry and bioinformatic expression analyses
- How this approach was used to identify 4 target candidates for CAR T cell- based immunotherapy of PDAC
SPEAKERS
You might also like
Engineering lipid nanoparticles for lung cancer imaging
Navigating CAR-T manufacturing: from research to GMP readiness
Assessing CAR-T cell therapy in vitro using patient-derived glioblastoma organoids
Rapid CAR-T cells: Accelerating manufacturing to enable fast transition of CAR-T cell therapies to the clinic
